The clinical relevance of the metabolism of prostate cancer; zinc and tumor suppression: connecting the dots

BackgroundThe genetic and molecular mechanisms responsible for and associated specifically with the development and progression of malignant prostate cells are largely unidentified. In addition, despite its implication in virtually all malignant cells, the role of altered cellular metabolism as an essential factor in prostate malignancy has been largely ignored. Moreover, the intermediary metabolism of normal prostate as well as malignant prostate cells is among the least studied and most poorly understood of all mammalian cells. Some important factors, especially the role of zinc, have been identified and implicated in the development and progression of prostrate malignancy. In this review, we provide a current and updated integrated assessment of the relationships of intermediary metabolism in normal prostate and in prostate cancer. The experimental and clinical evidence that leads to the formulation of concepts of normal and malignant prostate metabolism is presented. The evidence for a concept of zinc as a tumor suppressor agent and Zip1 zinc transporter as a tumor-suppressor gene is described.ResultsThe specialized function of the normal prostate glandular epithelium to produce and secrete enormously high levels of citrate involves and requires unique intermediary metabolism activities that are not generally associated with other normal mammalian cells. The accumulation of zinc by these cells is an essential factor in this unique metabolic relationship. In malignancy, the normal zinc-accumulating citrate-producing epithelial cells are metabolically transformed to citrate-oxidizing cells that lose the ability to accumulate zinc. A genetic alteration in the expression of ZIP1 zinc transporter is associated with this metabolic transformation. These genetic/metabolic relationships have important consequences on citrate-related metabolism, bioenergetics, cell proliferation and invasive capabilities of the malignant cells, which result in tumor-suppression characteristics.ConclusionThe genetic/metabolic relationships in normal prostate glandular epithelium are driven by the unique function to accumulate and secrete citrate. The genetic/metabolic transformation of the prostate malignant cells is driven by the metabolic/bioenergetic, growth/proliferative, and invasive/migration requirements of the malignant process. Zinc is critical to these relationships. An understanding of these genetic/metabolic relationships provides new directions and opportunities for development of regimens for the prevention and treatment of prostate cancer. Important insight into the genetic/metabolic requirements of the prostate malignant process is now evolving. Most importantly at this time, an appreciation and recognition of the genetic/metabolic significance and implications in the development of prostate malignancy is imperative; and much needed research in this area is essential. Hopefully, this review will help to achieve these goals.

[1]  C. Beaumont,et al.  Differential subcellular localization of hZip1 in adherent and non‐adherent cells , 2001, FEBS letters.

[2]  L. Baggetto,et al.  Deviant energetic metabolism of glycolytic cancer cells. , 1992, Biochimie.

[3]  G. Semenza,et al.  Oncogenic alterations of metabolism. , 1999, Trends in biochemical sciences.

[4]  P S Coleman,et al.  Enhanced rate of citrate export from cholesterol-rich hepatoma mitochondria. The truncated Krebs cycle and other metabolic ramifications of mitochondrial membrane cholesterol. , 1984, The Journal of biological chemistry.

[5]  J. Trapman.  Molecular mechanisms of prostate cancer. , 2001, European journal of cancer.

[6]  O. Bagasra,et al.  Zinc and Prostate Cancer: A Critical Scientific, Medical, and Public Interest Issue (United States) , 2005, Cancer Causes & Control.

[7]  D. Dietzen,et al.  Oxidation of pyruvate, malate, citrate, and cytosolic reducing equivalents by AS-30D hepatoma mitochondria. , 1993, Archives of biochemistry and biophysics.

[8]  P. Pedersen,et al.  Tumor mitochondria and the bioenergetics of cancer cells. , 1978, Progress in experimental tumor research.

[9]  Daniel E Bauer,et al.  ATP citrate lyase inhibition can suppress tumor cell growth. , 2005, Cancer cell.

[10]  O. Bagasra,et al.  Prostate Cancer in African American Men Is Associated With Downregulation of Zinc Transporters , 2003, Applied immunohistochemistry & molecular morphology : AIMM.

[11]  R. Franklin,et al.  Metabolic Diagnosis of Prostate Cancer by Magnetic Resonance Spectroscopy , 2002 .

[12]  I. Loikkanen,et al.  Expression of cytosolic acetyl-CoA synthetase gene is developmentally regulated , 2002, Mechanisms of Development.

[13]  R. Franklin,et al.  Evidence for a Zinc Uptake Transporter in Human Prostate Cancer Cells Which Is Regulated by Prolactin and Testosterone* , 1999, The Journal of Biological Chemistry.

[14]  R. Uzzo,et al.  Zinc inhibits nuclear factor-kappa B activation and sensitizes prostate cancer cells to cytotoxic agents. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  R. Franklin,et al.  Zinc induces mitochondria apoptogenesis in prostate cells. , 2000, Molecular urology.

[16]  R. Franklin,et al.  High‐affinity L‐aspartate transporter in prostate epithelial cells that is regulated by testosterone , 1993, The Prostate.

[17]  R. Franklin,et al.  Concepts of citrate production and secretion by prostate: 2. Hormonal relationships in normal and neoplastic prostate , 1991, The Prostate.

[18]  R. Franklin,et al.  Mitochondrial function, zinc, and intermediary metabolism relationships in normal prostate and prostate cancer. , 2005, Mitochondrion.

[19]  R. Franklin,et al.  Human ZIP1 is a major zinc uptake transporter for the accumulation of zinc in prostate cells. , 2003, Journal of inorganic biochemistry.

[20]  V. Ganapathy,et al.  Functional Identification of SLC5A8, a Tumor Suppressor Down-regulated in Colon Cancer, as a Na+-coupled Transporter for Short-chain Fatty Acids* , 2004, Journal of Biological Chemistry.

[21]  R. Franklin,et al.  EAAC1 is expressed in rat and human prostate epithelial cells; functions as a high-affinity L-aspartate transporter; and is regulated by prolactin and testosterone , 2006, BMC Biochemistry.

[22]  E. Horwitz,et al.  Diverse effects of zinc on NF-kappaB and AP-1 transcription factors: implications for prostate cancer progression. , 2006, Carcinogenesis.

[23]  V. Ganapathy,et al.  Biological functions of SLC5A8, a candidate tumour suppressor. , 2005, Biochemical Society transactions.

[24]  J. Kelleher,et al.  Analysis of tricarboxylic acid-cycle metabolism of hepatoma cells by comparison of 14CO2 ratios. , 1987, The Biochemical journal.

[25]  R. Franklin,et al.  ‘Why do tumour cells glycolyse?’: From glycolysis through citrate to lipogenesis , 2005, Molecular and Cellular Biochemistry.

[26]  P. Härkönen,et al.  Indirect androgenic control of citrate accumulation in rat ventral prostate. , 1982, Archives of andrology.

[27]  S. Zaichick,et al.  Zinc in the human prostate gland: Normal, hyperplastic and cancerous , 1997, International Urology and Nephrology.

[28]  R. Franklin,et al.  Evidence for two aspartate transport systems in prostate epithelial cells , 1990, The Prostate.

[29]  A. Iwama,et al.  Acetyl-coenzyme A synthetase is a lipogenic enzyme controlled by SREBP-1 and energy status. , 2002, American journal of physiology. Endocrinology and metabolism.

[30]  R. Franklin,et al.  Inhibitory effect of zinc on human prostatic carcinoma cell growth , 1999, The Prostate.

[31]  O. Bagasra,et al.  hZIP1 zinc uptake transporter down regulation and zinc depletion in prostate cancer , 2005, Molecular Cancer.

[32]  R. Franklin,et al.  Zinc Inhibition of Mitochondrial Aconitase and Its Importance in Citrate Metabolism of Prostate Epithelial Cells* , 1997, The Journal of Biological Chemistry.

[33]  M. Tatematsu,et al.  Aminopeptidase N regulated by zinc in human prostate participates in tumor cell invasion , 2001, International journal of cancer.

[34]  R. Franklin,et al.  Concepts of citrate production and secretion by prostate 1. Metabolic relationships , 1991, The Prostate.

[35]  PROSTATIC secretion. , 1952, Medical world.

[36]  R. Franklin,et al.  Direct effect of zinc on mitochondrial apoptogenesis in prostate cells , 2002, The Prostate.

[37]  C. Coopersmith,et al.  Epithelial cells , 1991 .

[38]  E. Pomare,et al.  Carbohydrate fermentation in the human colon and its relation to acetate concentrations in venous blood. , 1985, The Journal of clinical investigation.

[39]  R. Franklin,et al.  ZINC AND ZINC TRANSPORTERS IN NORMAL PROSTATE FUNCTION AND THE PATHOGENESIS OF PROSTATE CANCER , 2005 .

[40]  M. Toyota,et al.  Aberrant Methylation and Histone Deacetylation Associated with Silencing of SLC5A8 in Gastric Cancer , 2004, Tumor Biology.

[41]  R. Franklin,et al.  Prostate epithelial cells utilize glucose and aspartate as the carbon sources for net citrate production , 1989, The Prostate.

[42]  P. Härkönen.  Androgenic control of glycolysis, the pentose cycle and pyruvate dehydrogenase in the rat ventral prostate. , 1981, Journal of steroid biochemistry.

[43]  J. Kurhanewicz,et al.  Combined magnetic resonance imaging and spectroscopic imaging approach to molecular imaging of prostate cancer , 2002, Journal of magnetic resonance imaging : JMRI.

[44]  E. Newsholme,et al.  Maximum activities of key enzymes of glycolysis, glutaminolysis, pentose phosphate pathway and tricarboxylic acid cycle in normal, neoplastic and suppressed cells. , 1990, The Biochemical journal.

[45]  C. Plass,et al.  SLC5A8, a sodium transporter, is a tumor suppressor gene silenced by methylation in human colon aberrant crypt foci and cancers , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[46]  P. Carroll,et al.  Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24-0.7-cm3) spatial resolution. , 1996, Radiology.

[47]  R. Franklin,et al.  Terminal oxidation and the effects of zinc in prostate versus liver mitochondria. , 2004, Mitochondrion.

[48]  H. Sasano,et al.  A novel acyl-CoA synthetase, ACS5, expressed in intestinal epithelial cells and proliferating preadipocytes. , 1998, Journal of biochemistry.

[49]  M. van der Graaf,et al.  In vivo proton MR spectroscopy reveals altered metabolite content in malignant prostate tissue. , 1997, Anticancer research.

[50]  G P Liney,et al.  In vivo quantification of citrate concentration and water T2 relaxation time of the pathologic prostate gland using 1H MRS and MRI. , 1997, Magnetic resonance imaging.

[51]  P. Härkönen,et al.  Studies on the mechanism of testosterone action on glucose metabolism in the rat ventral prostate. , 1975, Journal of steroid biochemistry.

[52]  L. Sillerud,et al.  Differentiation of human tumors from nonmalignant tissue by natural‐abundance 13C NMR spectroscopy , 1988, Magnetic resonance in medicine.

[53]  P. Coleman,et al.  Continuous pyruvate carbon flux to newly synthesized cholesterol and the suppressed evolution of pyruvate-generated CO2 in tumors: further evidence for a persistent truncated Krebs cycle in hepatomas. , 1986, Biochimica et biophysica acta.

[54]  Z. Hall.  Cancer , 1906, The Hospital.

[55]  M. Romero,et al.  The human tumour suppressor gene SLC5A8 expresses a Na+–monocarboxylate cotransporter , 2004, The Journal of physiology.

[56]  S. Hayward,et al.  Evidence that the prostate-specific antigen (PSA)/Zn2+ axis may play a role in human prostate cancer cell invasion. , 2004, Cancer letters.

[57]  Franz Wind,et al.  Über den Stoffwechsel von Tumoren im Körper , 1926, Klinische Wochenschrift.

[58]  R. Franklin,et al.  The Intermediary Metabolism of the Prostate: A Key to Understanding the Pathogenesis and Progression of Prostate Malignancy , 2000, Oncology.

[59]  J. Stanford,et al.  Genetics of prostate cancer: too many loci, too few genes. , 2000, American journal of human genetics.

[60]  M. De la Fuente,et al.  Characterization of aconitate hydratase from mitochondria and cytoplasm of ascites tumor cells. , 1988, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[61]  P. Narayan,et al.  Citrate in the diagnosis of prostate cancer , 1999, The Prostate.

[62]  F. Borson‐Chazot,et al.  0021-972X/05/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 90(5):3028–3035 Printed in U.S.A. Copyright © 2005 by The Endocrine Society doi: 10.1210/jc.2004-1394 Silencing of the Tumor Suppressor Gene SLC5A8 Is Associated with BRAF Mutations , 2022 .

[63]  R. Franklin,et al.  Citrate modulation of high-affinity aspartate transport in prostate epithelial cells. , 1993, Cellular and molecular biology.

[64]  Liping Huang,et al.  Decreased intracellular zinc in human tumorigenic prostate epithelial cells: a possible role in prostate cancer progression , 2006, Cancer Cell International.

[65]  Keshav K. Singh,et al.  Mitochondrial aconitase and citrate metabolism in malignant and nonmalignant human prostate tissues , 2006, Molecular Cancer.